

Anti-CLEC12A/CD371 Antibody (Tepoditamab)

Introduction

Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A on bone marrow cells and CD3 on cytotoxic T cells. CLEC12A is a bone marrow differentiation antigen. Tepoditamab (MCLA-117) can kill AML leukemia blasts and AML leukemia stem cells, induce T cell-mediated proliferation and lysis of acute myeloid cells, and can be used in acute myeloid leukemia (AML) research.

Product parameters

Alternative Names	MCLA-117
Target Accession	Q5QGZ9
Target	CLEC12A / CD371
CAS number	2044679-53-8
Molecular Weight	144.73 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

